Paul J. Mellett - Feb 9, 2023 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Treasurer and CFO
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Feb 9, 2023
Transactions value $
-$268,816
Form type
4
Date filed
2/13/2023, 06:58 PM
Previous filing
Jan 10, 2023
Next filing
Feb 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Sale -$225K -4.2K -4.75% $53.64 84.3K Feb 9, 2023 Direct F1, F2
transaction ENTA Common Stock Sale -$43.5K -800 -0.95% $54.41 83.5K Feb 9, 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2022.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.09 to $54.05, inclusive.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.09 to $54.85, inclusive.

Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 above.